Board Director Changes
Avacta Group PLC announced board director changes effective June 22, 2026, with non-executive Director Richard Hughes set to become non-executive Chairman, succeeding Shaun Chilton who will not seek re-election but will remain as an advisor. Hughes brings over 30 years of corporate finance experience, having been a founder shareholder of boohoo.com and a director of Zeus Group. The company is also actively recruiting for a non-executive Deputy Chairman with international biotechnology expertise to support its pipeline development and partner engagement.
Select text to share a quote on X · sign in to keep highlights & notes in your AVCT notes
| LONDON and PHILADELPHIA - May 29, 2026 - Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre | CISION®, a tumor-activated oncology delivery platform, today announced that Richard Hughes, one of Avacta's non-executive Directors, will become non-executive Chairman of Avacta following the Annual General Meeting (AGM) on June 22, 2026. |
Shaun Chilton, who was appointed to the Board in 2022 and has served as non-executive Chairman since 2024, has decided not to seek re-election at the AGM. He will remain available to the Company as an advisor to the CEO and Board of Directors.
Richard Hughes was appointed a non-executive Director in May 2025. He has had a long and successful career in UK capital markets with over 30 years' corporate finance experience. He was a founder shareholder and a director of boohoo.com and a majority shareholder of Crawford Healthcare. He is a Director of Zeus Group.
The Company is conducting a recruitment process for a non-executive Deputy Chairman who will serve as the Senior Independent Director, with proven international expertise in the biotechnology sector, to support the Board as it guides the company through the ongoing development of its pipeline and engagement with potential partners from the pharma sector. The process is currently ongoing to recruit an individual to fill these roles.
Christina Coughlin, CEO of Avacta, commented:
| "On behalf of the Board, I would like to thank Shaun for his considerable contribution over the last four years as a Director, and most recently as our Chairman. During Shaun's tenure, Avacta has become a tightly focused clinical-stage biotechnology company developing valuable cancer therapeutics from its increasingly validated proprietary pre | CISION® platform. I am deeply grateful for his leadership and the strong working relationship we have shared throughout this ongoing transition. We wish him all the best. |
| "We are delighted to welcome Richard Hughes as Avacta's non-executive Chairman as part of this transition plan. Richard brings extensive experience which will be important for Avacta as we continue to deliver on the unique advantages of our pre | CISION® platform, now with two products progressing through clinical development. I look forward to working with Richard in his new capacity as Chairman." |
About FAP-Exd (AVA6103)
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.